|
注册号: Registration number: |
ChiCTR2500095393 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-07 09:43:04 |
|
注册时间: Date of Registration: |
2025-01-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
止血绷带HemCon Bandage用于血小板减少症患者介入治疗后穿刺点止血的有效性及安全性研究 |
|
Public title: |
Study on the effectiveness and safety of HemCon Bandage to stop bleeding at the femoral artery puncture point in patients with thrombocytopenia |
|
注册题目简写: |
止血绷带Hemcon Bandage 的有效性和安全性研究 |
|
English Acronym: |
Study on the effectiveness and safety of HemCon Bandage to stop bleeding |
|
研究课题的正式科学名称: |
止血绷带HemCon Bandage用于血小板减少症患者介入治疗后穿刺点止血的有效性及安全性研究 |
|
Scientific title: |
Study on the effectiveness and safety of HemCon Bandage to stop bleeding at the femoral artery puncture point in patients with thrombocytopenia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蒲美辰 |
研究负责人: |
刘畅 |
|
Applicant: |
Pu Meichen |
Study leader: |
Chang Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 159 2850 3423 |
研究负责人电话:
Study leader's |
+86 189 8060 6382 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
819441962@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
westchina_lc@foxmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
Study leader's address: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024年审(2366)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-25 00:00:00 | ||
|
伦理委员会联系人: |
彭淑贤 |
||
|
Contact Name of the ethic committee: |
Peng Suxian |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8550 3401 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
企业提供 |
||||||||||||||||||||||
|
Source(s) of funding: |
Enterprise supply |
||||||||||||||||||||||
|
研究疾病: |
血小板减少症 |
||||||||||||||||||||||
|
Target disease: |
thrombocytopenia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
1. 主要目的:本研究拟对血小板减少症患者(血小板计数低于100x10⁹/L)接受经股动脉穿刺介入治疗(含现场拔管及导管留置时间超过3小时),以止血绷带 HemCon Bandage进行按压止血。旨在评估止血绷带用于此类患者穿刺点止血的有效性及安全性。以期为血小板减少症患者接受介入治疗术后的快速安全止血提供临床依据。 2. 次要目的:评估接受止血绷带按压止血患者的舒适度 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Main Objective: In this study, patients with thrombocytopenia (platelet count less than 100x10^9/L) are proposed to receive femoral artery puncture interventional therapy (including on-site extubation and catheter retention time more than 3 hours), and use HemCon Bandage to press hemostasis. To evaluate the efficacy and safety of hemostatic bandages for hemostasis at puncture sites in these patients. In order to provide clinical basis for rapid and safe hemostasis in patients with thrombocytopenia after interventional therapy. 2. Secondary objective: To evaluate the comfort of patients receiving hemostatic bandage for hemostasis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)无法接受介入治疗的患者; (2)ATPP/PT/TT延长者,否则易发生迟发性出血 (3)在入组前14天内有活动性严重临床感染( >2级,NCI-CTCAE版本4.0 ),包括活动性结核病; (4)已知或自我报告感染艾滋病毒; (5)未控制的全身性疾病,如控制不良的糖尿病; (6)已知对研究药物的任何成分有超敏反应或过敏反应; (7)研究者判断任何不稳定的或可能危及受试者安全性及其对研究的依从性的状况;能致使受试者不能遵循研究计划甚至危及患者安全的合并症或社会环境。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients who cannot receive interventional treatment; (2) Prolonged ATPP/PT/TT, otherwise prone to delayed bleeding (3) Active severe clinical infection (> Grade 2, NCI-CTCAE version 4.0) within 14 days prior to enrollment, including active tuberculosis; (4) Known or self-reported HIV infection; (5) uncontrolled systemic diseases, such as poorly controlled diabetes; (6) known hypersensitivity or allergic reaction to any component of the investigational drug; (7) any condition that the investigator determines to be unstable or likely to compromise the subject's safety and compliance with the study; Comorbidities or social circumstances that could prevent subjects from following the study plan or even endanger patient safety. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2025-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-10 00:00:00 至 To 2025-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |